JMP Securities Raises DBV Technologies (NASDAQ:DBVT) Price Target to $5.00

DBV Technologies (NASDAQ:DBVT) had its price objective boosted by JMP Securities from $4.00 to $5.00 in a research note published on Wednesday morning, Benzinga reports. The brokerage currently has a market outperform rating on the stock.

DBVT has been the subject of a number of other reports. StockNews.com initiated coverage on DBV Technologies in a research report on Thursday, July 25th. They issued a hold rating for the company. HC Wainwright decreased their target price on DBV Technologies from $20.00 to $10.00 and set a buy rating for the company in a research report on Wednesday, May 8th.

DBV Technologies Stock Performance

NASDAQ:DBVT opened at $0.94 on Wednesday. The stock has a market cap of $90.70 million, a P/E ratio of -1.12 and a beta of 0.68. DBV Technologies has a 1 year low of $0.50 and a 1 year high of $3.70. The stock has a 50-day simple moving average of $0.91 and a 200-day simple moving average of $1.32.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 66.96%. During the same period last year, the company earned ($0.26) earnings per share. On average, equities research analysts predict that DBV Technologies will post -1.22 EPS for the current year.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Cowen AND Company LLC acquired a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 50,986 shares of the company’s stock, valued at approximately $49,000. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.